Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors
- Registration Number
- NCT03261011
- Lead Sponsor
- Akesobio Australia Pty Ltd
- Brief Summary
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK104 as a single agent in adult subjects with advanced solid tumor malignancies. The study consists of a dose escalation phase (Phase 1a) to determine the maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D) for AK104 as a single agent, and a dose expansion phase (Phase 1b) which will characterize treatment of AK104 as a single agent at the MTD or RP2D.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 119
- Written and signed informed consent and any locally required authorization obtained from the subject/legal representative.
- In dose-escalation cohorts (Phase 1a), histologically or cytologically documented advanced or metastatic solid tumor that is refractory/relapsed to standard therapies, or for which no effective standard therapy is available, or the subject refuses standard therapy.
- In the dose-expansion cohorts (Phase 1b), histologically or cytologically confirmed selected advanced solid tumors (to be determined). Subjects must have received no more than three prior lines of systemic therapy for advanced or metastatic disease.
- Subject must have at least one measurable lesion according to RECIST Version1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
- Available archived tumor tissue sample to allow for correlative biomarker studies. In the setting where archival material is unavailable or unsuitable for use, the subject must consent and undergo fresh tumor biopsy.
- Adequate organ function.
- History of severe hypersensitivity reactions to other mAbs.
- Prior exposure to any anti-PD-1, anti-PD-L1, anti-CTL4 antibody or any other antibody or drug targeting T-cell costimulation or checkpoint pathways such as ICOS, or agonists such as CD40, CD137, GITR, OX40 etc.
- Receipt of any immunotherapy, any conventional or investigational systemic anticancer therapy within 4 weeks prior to the first dose of AK104; in the case of mAbs, 6 weeks prior to the first dose of AK104.
- Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. Concurrent use of hormones for non-cancer-related conditions is acceptable.
- Subjects with a condition requiring systemic treatment with either corticosteroid (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration.
- Active or prior documented autoimmune disease within the past 2 years.
- Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
- History of primary immunodeficiency.
- History of organ transplant or hematopoietic stem cell that requires use of immunosuppressives.
- Known allergy or reaction to any component of the AK104 formulation.
- History of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapies.
- Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.
- Known history of tuberculosis.
- Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
- Any positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection except for subjects with HCC.
- An active infection requiring systemic therapy with the exception of anti-viral therapy for hepatitis as specified by the protocol.
- Receipt of live or attenuated vaccination within 30 days prior to the first dose of AK104.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description AK-104 AK-104 Single-arm
- Primary Outcome Measures
Name Time Method Number of participants with a Dose Limiting Toxicity (DLT) During the first 4 weeks DLTs will be assessed during the first 4 weeks of treatment for dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria, and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle (4 weeks) of treatment.
Number of participants with adverse events (AEs) From the time of informed consent signed through 90 days after the last dose of AK104, up to 2 years and 3 months An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.
- Secondary Outcome Measures
Name Time Method Number of subjects who develop detectable anti-drug antibodies (ADAs) From first dose of AK104 through to 90 days after last dose of AK104; Up to 2 years and 3 months. The immunogenicity of AK104 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs).
Disease control rate (DCR) Up to 3 years The DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥8 weeks) based on RECIST Version 1.1.
Minimum observed concentration (Cmin) of AK104 at steady state From first dose of AK104 through to 90 days after last dose of AK104; Up to 2 years and 3 months. The endpoints for assessment of PK of AK104 include serum concentrations of AK104 at different timepoints after AK104 administration.
Objective response rate (ORR) Up to 3 years The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1.
Progression-free survival (PFS) Up to 3 years Progression-free survival is defined as the time from the start of treatment with AK104 until the first documentation of disease progression or death due to any cause, whichever occurs first.
Duration of response (DoR) Up to 3 years Duration of response is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.
Overall survival (OS) Up to 3 years Overall survival is defined as the time from the start of treatment with AK104 until death due to any cause.
Area under the curve (AUC) of AK104 From first dose of AK104 through 90 days after last dose of AK104; Up to 2 years and 3 months. The endpoints for assessment of PK of AK104 include serum concentrations of AK104 at different timepoints after AK104 administration.
Maximum observed concentration (Cmax) of AK104 From first dose of AK104 through to 90 days after last dose of AK104; Up to 2 years and 3 months. The endpoints for assessment of PK of AK104 include serum concentrations of AK104 at different timepoints after AK104 administration.
Trial Locations
- Locations (6)
Integrated Clinical Oncology Network (ICON)
🇦🇺South Brisbane, Queensland, Australia
St Vincent's Hospital Sydney
🇦🇺Darlinghurst, New South Wales, Australia
Monash Health
🇦🇺Clayton, Victoria, Australia
Austin Health
🇦🇺Heidelberg, Victoria, Australia
Peter MacCallum Cancer Centre
🇦🇺Melbourne, Victoria, Australia
Linear Clinical Research/Sir Charles Gairdner Hospital
🇦🇺Nedlands, Western Australia, Australia